Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts.

ABSTRACT: Several therapeutic options are available for metastatic RCC, but responses are almost never complete, and resistance to therapy develops in the vast majority of patients. Consequently, novel treatments are needed to combat resistance to current therapies and to improve patient outcomes. We have applied integrated transcriptome and proteome analyses to identify cathepsin B (CTSB), a cysteine proteinase of the papain family, as one of the most highly upregulated gene products in established human RCC xenograft models of resistance to vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI). We used established RCC models to test the significance of CTSB in the progression of renal cancer. Our evaluation of CTSB showed that stable CTSB knockdown suppressed RCC gro

SUBMITTER: Chen CH 

PROVIDER: S-EPMC6386754 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature